CSF amyloid-β peptides in neuropathologically diagnosed dementia with lewy bodies and alzheimer's disease

Journal of Alzheimer's Disease

Volumn 24, Issue 2, 2011, Pages 383-391

  Mollenhauer, Brit ^a   Esselmann, Herrmann ^b   Trenkwalder, Claudia ^a   Schulz Schaeffer, Walter ^a   Kretzschmar, Hans ^c   Otto, Markus ^d   Wiltfang, Jens ^b   Mirko, Brit ^b  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF ULM   (Germany)

Author keywords

Alzheimer's disease; amyloid peptides; cerebrospinal fluid; dementia with Lewy bodies; neuropathologically confirmed diagnosis

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42];

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN LEVEL; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; CORRELATIONAL STUDY; DIFFUSE LEWY BODY DISEASE; DISEASE MARKER; FEMALE; HUMAN; IMMUNOBLOTTING; MAJOR CLINICAL STUDY; MALE; NEUROPATHOLOGY; PHENOTYPE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS;

EID: 79955640893     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2011-101551     Document Type: Article

References (24)

1. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-TortosaE, Halliday G, HansenLA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65, 1863-1872. (Pubitemid 43970103)
2. Bibl M, Mollenhauer B, Esselmann H, Lewczuk P, Klafki HW, Sparbier K, Smirnov A, Cepek L, Trenkwalder C, Rüther E, Kornhuber J, Otto M, Wiltfang J (2006) CSF amyloid-ß-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia. Brain 129, 1177-1187.
3. Bibl M, Mollenhauer B, Lewczuk P, Esselmann H, Wolf S, Trenkwalder C, Otto M, Stiens G, Rüther E, Kornhuber J, Wiltfang J (2007) Validation of amyloid-ß peptides in CSF diagnosis of neurodegenerative dementias. Mol Psy 12, 671-680. (Pubitemid 46998250)
4. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82, 239-259.
5. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L (1991) The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neu-rology 41, 479-486.
6. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944. (Pubitemid 14076461)
7. World Medical Organisation (1996) Declaration of Helsinki. BrMedJ313, 1448-1449.
8. Zerr I, Bodemer M, Gefeller O, Otto M, Poser S, Wiltfang J, Windl O, Kretzschmar HA, Weber T (1998) Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt-Jakob disease. Ann Neurol 43, 32-40. (Pubitemid 28124646)
9. Bibl M, Esselmann H, Otto M, Lewczuk P, Cepek L, Rüther E, Kornhuber J, Wiltfang J (2004) Cerebrospinal fluid (CSF) amyloid beta (Aß) peptide patterns in Alzheimer's disease (AD) patients and non-demented controls depend on sample pre-treatment: indication of carrier-mediated epitope masking of Aß peptides. Electrophoresis 25, 2912-2918. (Pubitemid 39294839)
10. Wiltfang J, Esselmann H, Bibl M, Smirnov A, Otto M, Paul S, Schmidt B, Klafki HW, Maler M, Dyrks T, Bienert M, Beyermann M, Rüther E, Kornhuber J (2002) Highly con-served and disease-specific patterns of carboxyterminally truncatedAbetapeptides 1-37/38/39inadditionto 1-40/42in Alzheimer's disease and patients with chronic neuroinflam-mation. J Neurochem 81, 481-496. (Pubitemid 34809327)
11. The Working Group on: "Molecular and Biochemical Mark-ers of Alzheimer's Disease (1998) Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Neurobiol Aging 19, 109-116.
12. Wiltfang J, Esselmann H, Bibl M, Hüll M, Hampel H, Kessler H, Frölich L, Schröder J, Peters O, Jessen F, Luckhaus C, Perneczky R, Jahn H, Fiszer M, Maler JM, Zimmermann R, Bruckmoser R, Kornhuber J, Lewczuk P (2007) Amyloid ß peptide ratio 42/40 but not Aß42 correlates with phospho-Tau in patients with low-and high-CSF Aß40. J Neurochem 101, 1053-1059. (Pubitemid 46683864)
13. van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM (2006) Plasma Abeta(1-40) and Abeta(1-42) andthe risk of dementia: a prospective case-cohort study. Lancet Neurol 5, 655-660. (Pubitemid 44062411)
14. Bibl M, Esselmann H, Mollenhauer B, Weniger G, Welge V, Liess M, Lewczuk P, Otto M, Schulz JB, Trenkwalder C, Kornhuber J, Wiltfang J (2007) Blood-based neurochemical diagnosis of vascular dementia: a pilot study. J Neurochem 103, 467-474. (Pubitemid 47498016)
15. Mollenhauer B, Cullen V, Kahn I, Krastins B, Outeiro TF, Pepivani I, Ng J, Schulz-Schaeffer W, Kretzschmar HA, McLean PJ, Trenkwalder C, Sarracino DA, Vonsattel JP, Locascio JJ, El-Agnaf OM, Schlossmacher MG (2008) Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol 213, 315-325.
16. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, LaRossa GN, Spinner ML, Klunk WE, Mathis CA, DeKosky ST, Morris JC, Holtzman DM (2006) Inverse rela-tion between in vivo amyloid imaging load and cerebrospinal fluid Aß42 in humans. Ann Neurol 59, 512-519. (Pubitemid 43358072)
17. Wiltfang J, Esselmann H, Smirnov A, Bibl M, Cepek L, Steinacker P, Mollenhauer B, Buerger K, Hampel H, Paul S, Neumann M, Maler M, Zerr I, Kornhuber J, Kretzschmar HA, Poser S, Otto M (2003) Beta-amyloid peptides in cere-brospinal fluid of patients with Creutzfeldt-Jakob disease. AnnNeurol 54, 263-267. (Pubitemid 36909629)
18. Bibl M, Lewczuk P, Esselmann H, Mollenhauer B, Klafki HW, Welge V, Wolf S, Trenkwalder C, Otto M, Kornhuber J, Wiltfang J (2008) CSF amyloid-ß 1-38 and 1-42 in FTD and AD: biomarker performance critically depends on the detergent accessible fraction. Proteomics Clin Appl 2, 1548-1556.
19. Eckman EA, Eckman CB (2005) Aß-degrading enzymes: modulators of Alzheimer's disease pathogenesis and targets for therapeutic intervention. Biochem Soc Trans 33, 1101-1105. (Pubitemid 41659123)
20. Giacomelli CE, Norde W (2005) Conformational changes in the amyloid ß peptide (1-40) adsorbed on solid surfaces. Macromol Biosci 5, 401-407. (Pubitemid 40813976)
21. Yoshimoto M, Iwai A, Kang D, Otero DA, Xia Y, Saitoh T (1995) NACP, the precursor of the non-amyloid beta/A4 protein (A beta) component of Alzheimer disease amyloid, binds A beta and stimulates A beta aggregation. Proc Natl AcadSci USA 92, 9141-9145.
22. Pletnikova O, West N, Lee MK, Rudow GL, Skolasky RL, Dawson TM, Marsh L, Troncoso JC (2005) Aß deposition is associated with enhanced cortical α-synuclein lesions in Lewy body diseases. Neurobiol Aging 26, 1183-1192. (Pubitemid 40726011)
23. Mandal PK, Pettegrew JW, Masliah E, Hamilton RL, Mandal R (2006) Interaction between Abeta peptide and alpha synu-clein: molecular mechanisms in overlapping pathology of Alzheimer's and Parkinson's dementia with Lewy body dis-ease. Neurochem Res 31, 1153-1162. (Pubitemid 44379676)
24. Kramer ML, Schulz-Schaeffer WJ (2007) Presynaptic α-synuclein aggregates, not Lewy Bodies, cause neurode-generation in dementia with Lewy bodies. J Neurosci 27, 1405-1410.